Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29984901 | 0.83 | CYP3A4 (0.61) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL550215 | 0.83 | CYP3A4 (0.61) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2808025 | 0.82 | CYP3A4 (0.48) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7833889 | 0.80 | CYP3A4 (0.67) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31026506 | 0.80 | CYP3A4 (0.67) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2929973 | 0.80 | CYP2C19 (0.56) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6693749 | 0.79 | CYP3A4 (0.70) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16346261 | 0.78 | ALDH1A1 (0.65) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1922269 | 0.78 | CYP3A4 (0.76) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31333138 | 0.77 | CYP3A4 (0.68) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009050237-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050235-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20080177085-A1 | Process for the Synthesis of a CPLA2 Inhibitor | DEHNHARDT CHRISTOPH M | 2008-07-24 | — | — | US | disclosed |
| US-7342119-B2 | Process for the synthesis of a CPLA2 inhibitor | WYETH HOLDINGS CORPORATION | 2008-03-11 | — | — | US | disclosed |
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | WYETH HOLDINGS CORPORATION (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | PLAA, PLA2G4A, PLA2G12A | CYP3A4 521/4885ALDH1A1 3682/4885CYP1A2 196/4885 |
| US-20080177085-A1 | Process for the Synthesis of a CPLA2 Inhibitor | PLAA, PLA2G4A, PLA2G12A | CYP3A4 521/4885ALDH1A1 3682/4885CYP1A2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.